Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

In Vitro Adenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer

  • Park, Seul-Kee (Department of Surgery, Yonsei University College of Medicine) ;
  • Woo, Yang-Hee (Department of Surgery, Yonsei University College of Medicine) ;
  • Kim, Ho-Geun (Department of Pathology, Yonsei University College of Medicine) ;
  • Lee, Yong-Chan (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Choi, Sung-Ho (ISU ABXIS Co., LTD.) ;
  • Hyung, Woo-Jin (Department of Surgery, Yonsei University College of Medicine) ;
  • Noh, Sung-Hoon (Department of Surgery, Yonsei University College of Medicine)
  • Received : 2010.10.05
  • Accepted : 2010.10.14
  • Published : 2010.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer. Materials and Methods: A total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer specimens using eleven chemotherapeutic agents - etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, docetaxel, paclitaxel, methotraxate, and cisplatin - for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell death rate, and the chemosensitivity index. Results: The failure rate of ATP-CRA was 1.6% (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5%. Etoposide showed the highest cell death rate (35.9%) while methotrexate showed the lowest (16.6%). The most active chemotherapeutic agent was etoposide, which most frequently ranked highest in the chemosensitivity test: 31.9% (51/160). Oxaliplatin was more active against early gastric cancers than advanced gastric cancers, whereas docetaxel was more active against advanced cancers. The lymph node negative group showed a significantly higher cell death rate than the lymph node positive group when treated with doxorubicin, epirubicin, and mitomycin. Conclusions: ATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of ATP-CRA should be evaluated by prospective studies comparing the regimen guided by ATP-CRA with an empirical regimen.

Keywords

References

  1. Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri E, La Vecchia C. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 2008;19:631-640.
  2. http://www.nhic.or.kr/ Accessed January 4, 2010
  3. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-242. https://doi.org/10.1046/j.1365-2168.2000.01360.x
  4. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730. https://doi.org/10.1056/NEJMoa010187
  5. Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, Mc-Clure S, Chapman RA, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995;2:488-494. https://doi.org/10.1007/BF02307081
  6. Hohler T, Mohler M. New chemotherapeutic options in advanced gastric cancer. Onkologie 2003;26(Suppl 7):54-59.
  7. Neale MH, Myatt NE, Khoury GG, Weaver P, Lamont A, Hungerford JL, et al. Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res 2001;11:601-609. https://doi.org/10.1097/00008390-200112000-00006
  8. Kang SM, Park MS, Chang J, Kim SK, Kim H, Shin DH, et al. A feasibility study of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) as a chemosensitivity test for lung cancer. Cancer Res Treat 2005;37:223-227. https://doi.org/10.4143/crt.2005.37.4.223
  9. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 1996;7:630-635. https://doi.org/10.1097/00001813-199608000-00002
  10. Huh JW, Park YA, Lee KY, Sohn SK. Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer-secondary publication. Yonsei Med J 2009;50:697-703. https://doi.org/10.3349/ymj.2009.50.5.697
  11. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000;77:258-263. https://doi.org/10.1006/gyno.2000.5728
  12. Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran EM. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep 1986;70:1283-1295.
  13. Bird MC, Bosanquet AG, Gilby ED. In vitro determination of tumour chemosensitivity in haematological malignancies. Hematol Oncol 1985;3:1-10. https://doi.org/10.1002/hon.2900030102
  14. Bogden AE, Griffin W, Reich SD, Costanza ME, Cobb WR. Predictive testing with the subrenal capsule assay. Cancer Treat Rev 1984;11(Suppl A):113-124. https://doi.org/10.1016/0305-7372(84)90050-1
  15. Rozencweig M, Hofmann V, Sanders C, Rombaut W, Fruh U, Martz G. In vitro growth of human malignancies in a cloning assay. Recent Results Cancer Res 1984;94:1-7.
  16. Tanigawa N, Kern DH, Hikasa Y, Morton DL. Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture. Cancer Res 1982;42:2159-2164.
  17. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-942.
  18. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoff man RM. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 1987;84:5029-5033. https://doi.org/10.1073/pnas.84.14.5029
  19. Freeman AE, Hoffman RM. In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 1986;83:2694-2698. https://doi.org/10.1073/pnas.83.8.2694
  20. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, et al. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983;43:1926-1931.
  21. Von Hoff DD, Kronmal R, Salmon SE, Turner J, Green JB, Bonorris JS, et al. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 1991;67:20-27. https://doi.org/10.1002/1097-0142(19910101)67:1<20::AID-CNCR2820670105>3.0.CO;2-U
  22. Xu JM, Song ST, Tang ZM, Jiang ZF, Liu XQ, Zhou L, et al. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat 1999;53:77-85. https://doi.org/10.1023/A:1006122912146
  23. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfi eld MR. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004;22:3631-3638. https://doi.org/10.1200/JCO.2004.05.065
  24. Cunningham D, Allum WH, Stenning SP, Th ompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. https://doi.org/10.1056/NEJMoa055531
  25. Neri B, Cini G, Andreoli F, Boffi B, Francesconi D, Mazzanti R, et al. Randomized trial of adjuvant chemotherapy versus control aft er curative resection for gastric cancer: 5-year followup. Br J Cancer 2001;84:878-880. https://doi.org/10.1054/bjoc.2000.1472
  26. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al.; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  27. Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, et al. In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol 2006;11:449-453. https://doi.org/10.1007/s10147-006-0618-x
  28. Iwahashi M, Nakamori M, Nakamura M, Noguchi K, Ueda K, Nakatani Y, et al. Individualized adjuvant chemotherapy guided by chemosensitivity test sequential to extended surgery for advanced gastric cancer. Anticancer Res 2005;25:3453-3459
  29. Park JY, Kim YS, Bang S, Hyung WJ, Noh SH, Choi SH, et al. ATP-based chemotherapy response assay in patients with unresectable gastric cancer. Oncology 2007;73:439-440. https://doi.org/10.1159/000136802
  30. Lee JH. Th e results of the ATP Based chemotherapy response assay in gastric cancer tissues. J Korean Gastric Cancer Assoc 2007;7:160-166. https://doi.org/10.5230/jkgca.2007.7.3.160

Cited by

  1. Diagnosis of 25 genotypes of human papillomaviruses for their physical statuses in cervical precancerous/cancerous lesions: a comparison of E2/E6E7 ratio-based vs. multiple E1-L1/E6E7 ratio-based dete vol.12, pp.None, 2010, https://doi.org/10.1186/s12967-014-0282-2
  2. Association between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study vol.15, pp.4, 2010, https://doi.org/10.5230/jgc.2015.15.4.223
  3. In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer vol.48, pp.3, 2016, https://doi.org/10.4143/crt.2015.140